Build and optimize your product and portfolio value.
Prepare for lasting clinical and commercial success when you build and optimize your product and portfolio value with us. Science-based, future-focused, and comprehensive, our strategies provide sound guidance for your most critical clinical development, opportunity prioritization, and go/no-go decisions.
With a unique blend of clinical and scientific expertise, innovative business strategy, and more than three decades of strategic experience, we advise on optimal and sustainable pharmaceutical portfolio analysis and diligence and early pipeline strategies.
Rooted in a strong understanding of the science and evolving market, we can help your cross–functional teams understand where to position their early–stage assets and platforms in the future landscape, and how to optimize their clinical development path and maximize the asset value.
We can help you with:
Get the latest insights and perspectives from our experts.
Putnam shares key questions to consider in preparation of advancing trials and deals that have been put on hold.
We explore two instances where our consulting teams used AssetNav to help clients prioritize promising BD&L opportunities in oncology.
Putnam experts share observations on recent global trends in the rare disease space and recommend strategies to maximize opportunities.
In recent years, we have observed increasing clinical development activity in autoimmune diseases, including for Myasthenia Gravis (MG).
Looking to get in touch with an expert or team member?
Tell us how we can help.
